Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of vater

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2715-2722

  Shiba, Hiroaki ^a   Misawa, Takeyuki ^a   Fujiwara, Yuki ^a   Futagawa, Yasuro ^a   Furukawa, Kenei ^a   Haruki, Koichiro ^a   Iwase, Ryota ^a   Wakiyama, Shigeki ^a   Ishida, Yuichi ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinoma of the ampulla of Vater; Glasgow prognostic score; Pancreaticoduodenectomy; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; BILIARY TRACT DRAINAGE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; LYMPH NODE METASTASIS; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS FISTULA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; SCORING SYSTEM; SURGICAL INFECTION; VATER PAPILLA CARCINOMA; BILE DUCT TUMOR; CARCINOMA OF THE AMPULLA OF VATER; INFLAMMATION; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VATER PAPILLA; VERY ELDERLY;

CARCINOMA OF THE AMPULLA OF VATER; GLASGOW PROGNOSTIC SCORE; PANCREATICODUODENECTOMY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; COMMON BILE DUCT NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PANCREATICODUODENECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84881336890     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Yamaguchi K and Enjoji M: Carcinoma of the ampulla of Vater: A clinicopathologic study and pathologic staging of 109 cases of carcinoma and five cases of adenoma. Cancer 59: 506-515, 1987.
2. Nakase A, Matsumoto Y, Uchida K and Honjo I: Surgical treatment of cancer of the pancreas and the periampullary region: Cumulative results in 57 institutions in Japan. Ann Surg 185: 52-57, 1977.
3. Warren KW, Choe DS, Plaza J and Relihan M: Results of radical resection for periampullary cancer. Ann Surg 181: 534-540, 1975.
4. Talamini MA, Moesinger RC, Pitt HA, Sohn TA, Hruban RH, Lillemoe KD, Yeo CJ and Cameron JL: Adenocarcinoma of the ampulla of Vater: A 28-year experience. Ann Surg 225: 590-600, 1997.
5. Yoon YS, Kim SW, Park SJ, Lee HS, Jang JY, Choi MG, Kim WH, Lee KU and Park YH: Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg 242: 92-100, 2005.
6. Hsu HP, Yang TM, Hsieh YH, Shan YS and Lin PW: Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 14: 50-60, 2007.
7. Park JS, Yoon DS, Kim KS, Choi JS, Lee WJ, Chi HS and Kim BR: Factors influencing recurrence after curative resection for ampulla of Vater carcinoma. J Surg Oncol 95: 286-290, 2007.
8. Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, Jang JY, Kim SW, Kang GH and Yoon YB: Recurrence and prognostic factors of ampullary carcinoma after radical resection: Comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol 14: 3195-3201, 2007.
9. Geer RJ and Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165: 68-72, 1993.
10. Han SS, Jang JY, Kim SW, Lee KU and Park YH: Analysis of long-term suvivors after resection for pancreatic cancer. Pancreas 32: 271-275, 2006.
11. Moon HJ, An JY, Heo JS, Cjoi SH, Joh JW and Kim YI: Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas 32: 37-43, 2006.
12. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, Madura JA, Wiebke EA and Lillemoe KD: A marginnegative R0 resection accomplished with minimal postoperative is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 10: 1338-1345, 2006.
13. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ and Coleman J: Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 161: 120-124, 1991.
14. Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small cell lung cancer. Br J Cancer 89: 1028-1030, 2003.
15. Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small cell lung cancer. Br J Cancer 90: 1704-1706, 2004.
16. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C and McMillan DC: Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94: 227-230, 2006.
17. Crumley AB, McMillan DC, McKernan M, McDonald AC and Stuart RC: Evaluation of an inflammation-based prognostic score in patients with inoperable gastroesophageal cancer. Br J Cancer 94: 637-641, 2006.
18. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW and McKay CJ: Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6: 450-453, 2006.
19. Ramsey S, Lamb GW, Aitchison M, Graham J and McMillan DC: Evaluation of an inflammation-based prognostic score in patients with inoperable renal cancer. Cancer 109: 205-212, 2007.
20. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG and McMillan DC: Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 97: 1266-1270, 2007.
21. McMillian DC, Crozier JE, Canna K, Angerson WJ and McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22: 881-886, 2007.
22. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ and Stuart RC: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 94: 1568-1571, 2006.
23. Hilmy M, Bartlett JM, Underwood MA and MaMillan DC: The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 92: 625-627, 2005.
24. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R and Imrie CW: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 92: 781-784, 2005.
25. Lamb GW, McMillan DC, Ramsey S and Aitchison M: The relationship between the preoperative systemic inflammatory response and cancer specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 94: 781-784, 2006.
26. Hara M, Matsuzaki Y, Shimizu T, Tomita M, Ayabe T, Enomoto Y and Onitsuka T: Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 27: 3001-3004, 2007.
27. Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y, Ogawa M, Ishida Y, Misawa T and Yanaga K: The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett 4: 324-328, 2012.
28. Fujiwara Y, Shiba H, Furukawa K, Iida T, Haruki K, Sakamoto T, Gocho T, Wakiyama S, Hirohara S, Ishida Y, Misawa T, Ohashi T and Yanaga K: Glasgow prognostic score is related to blood transfusion requirements and postoperative complications in hepatic resection for hepatocellular carcinoma. Anticancer Res 30: 5129-5136, 2010.
29. Moyes LH, Leitch EF, McKee RF, Anderson JH, Horgan PG and McMillan DC: Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. Br J Cancer 100: 1236-1239, 2009.
30. Nozoe T, Matsumata T and Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 23: 263-266, 2000.
31. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R and McArdle CS: Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 31: 101-105, 1998.
32. McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR and McArdle CS: Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39: 210-213, 2001.
33. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF and McArdle CS: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92: 651-654, 2005.
34. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Olah A, Rawcliffe CL, Verbeke CS, Campbell F and Buchler MW; European Study Group for Pancreatic Cancer: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. JAMA 308: 147-156, 2012.